ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment

Journal of Thrombosis and Haemostasis

Volumn 18, Issue 8, 2020, Pages 2060-2063

  Barrett, Christopher D ^a,b   Moore, Hunter B ^c   Yaffe, Michael B ^a,b   Moore, Ernest E ^c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

acute respiratory distress syndrome (ARDS); anticoagulation; COVID 19; disseminated intravascular coagulation; International Society on Thrombosis and Haemostasis (ISTH)

Indexed keywords

ALTEPLASE; D DIMER; FIBRINOGEN; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPERCOAGULABILITY; KIDNEY FAILURE; LETTER; LUNG EMBOLISM; LUNG INSUFFICIENCY; MEDICAL SOCIETY; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOSIS; BETACORONAVIRUS; CORONAVIRUS INFECTION; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083865938     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14860     Document Type: Letter

References (31)

1. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020. (ePub ahead of print).
2. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18:786-787.
3. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9:687-690.
4. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
6. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. [Epub ahead of print]. https://doi.org/10.1016/S2213-2600(20)30079-5
7. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020. [Epub ahead of print]. https://doi.org/10.1515/cclm-2020-0188
8. Xu J, Wang L, Zhao L, et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Respir Res Preprint 2020. https:doi.org/10.21203/rs.3.rs-18340/v1
9. Cotton RC, Shaikh MS, Dent RV. Heparin resistance and plasma fibrinogen in elderly subjects with and without occlusive vascular disease. J Atheroscler Res. 1968;8:959-966.
10. Klovaite J, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med. 2013;187:286-293.
11. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677-2678.
12. Kamphuisen P, Eikenboom J, Vos H, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680-683.
13. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms–the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719-722.
14. Harr JN, Moore EE, Chin TL, et al. Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis. Shock. 2014;41:33-39.
15. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323:1335.
16. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med. 1976;61:585-589.
17. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27:337-349.
18. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
19. Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novelcoronavirus pneumonia (COVID-19). Preprints (not peer reviewed); posted 9 March2020.
20. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(4):844-847.
21. Hardaway RM 3rd, Mc KD. Disseminated intravascular coagulation: a cause of shock. Ann Surg. 1959;149:462-470.
22. Hardaway RM, Brune WH, Geever EF, Burns JW, Mock HP. Studies on the role of intravascular coagulation in irreversible hemorrhagic shock. Ann Surg. 1962;155:241-250.
23. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24-33.
24. Matsuda T, Murakami M. Relationship between fibrinogen and blood viscosity. Thromb Res. 1976;8:25-33.
25. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020. [Epub ahead of print]. https://doi.org/10.1093/eurheartj/ehaa254
26. Naicker S, Yang C-W, Hwang S-J, et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824-828.
27. de Haan CA, Li Z, te Lintelo E, et al. Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. J Virol. 2005;79:14451-14456.
28. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med. 1990;18:1413-1418.
29. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med. 1998;25:184-188.
30. Liu C, Ma Y, Su Z, et al. Meta-analysis of preclinical studies of fibrinolytic therapy for acute lung injury. Front Immunol. 2018;9:1898.
31. Moore HB, Barrett CD, Moore EE, et al. Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)? J Trauma Acute Care Surg. 2020. [Epub ahead of print]. https://doi.org/10.1097/TA.0000000000002694